Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder characterized by the selective loss of upper and lower motor neurons in the brain and spinal cord. This comprehensive treatment guide covers disease-modifying therapies, symptomatic management, multidisciplinary care approaches, and emerging treatments for ALS and related motor neuron.
ALS results in progressive muscle weakness, paralysis, and ultimately respiratory failure, typically within 2-5 years of symptom onset[1]. Approximately 10% of cases are familial, with C9orf72, SOD1, FUS, and TARDBP being the most common genetic causes[2]. The remaining 90% are sporadic, with complex multifactorial etiology involving glutamate excitotoxicity, oxidative stress, mitochondrial dysfunction, neuroinflammation, and impaired RNA metabolism[3].
Riluzole (Rilutek)
Riluzole, approved in 1995, remains the cornerstone of disease-modifying therapy for ALS[4]. The drug acts primarily by inhibiting glutamate release, reducing excitatory neurotransmission, and modulating sodium channels[5]. Clinical trials demonstrated a 2-3 month survival benefit, with more pronounced effects in patients with bulbar-onset disease[6]. The standard dose is 50 mg twice daily, with monitoring of liver function due to potential hepatotoxicity[7]. Common side effects include dizziness, fatigue, and nausea[8].
Edaravone (Radicava)
Edaravone, approved in 2017, is a free radical scavenger that reduces oxidative stress, a key pathological mechanism in ALS[9]. The approval was based on the MCI186-19 trial showing reduced functional decline measured by ALSFRS-R score compared to placebo[10]. Treatment involves intravenous infusion for 14 days followed by 14-day drug-free periods[11]. Post-marketing studies suggest greater benefit in patients with earlier disease stage and better baseline function[12]. Common adverse effects include bruising, gait disturbance, and headache[13].
AMX0035 (Relyvrio)
AMX0035 (sodium phenylbutyrate/taurursodiol), approved in 2022, targets mitochondrial dysfunction and endoplasmic reticulum stress, two interconnected pathways in ALS pathogenesis[14]. The CENTAUR trial demonstrated significant survival benefit (median 9.7 months) and slower functional decline compared to placebo[15]. The drug is administered orally as a powder mixed with water, with dosing initiated at 1 packet daily for 3 weeks, then increased to 1 packet twice daily[16]. Common side effects include diarrhea, abdominal pain, and nausea[17].
Tofersen (Qalsody)
Tofersen, approved in 2023, is an antisense oligonucleotide (ASO) therapy specifically targeting SOD1 gene mutations, which account for approximately 2% of all ALS cases[18]. The VALOR trial demonstrated significant reduction in SOD1 protein and neurofilament light chain (NfL) levels, with a trend toward clinical benefit in the open-label extension[19]. Treatment involves intrathecal administration every 28 days, requiring lumbar puncture or implanted intrathecal port[20]. Patients must have confirmed SOD1 mutation to receive treatment[21].
Lamotrigine
This anti-epileptic drug blocks voltage-gated sodium channels and reduces glutamate release[22]. Retrospective analyses suggest possible modest benefit in bulbar-onset ALS, though prospective trials are lacking[23].
Minocycline
This antibiotic with anti-inflammatory properties showed promise in preclinical models but failed to demonstrate benefit in Phase III trials[24].
Lithium
While early studies suggested neuroprotective effects, a large randomized trial (LIT-ALS) did not confirm clinical benefit[25].
Mexiletine
This sodium channel blocker effectively reduces muscle cramps in ALS, with the phase II BEST-I trial demonstrating significant reduction in cramp frequency and severity[26]. Starting dose is 150 mg daily, titrated to 300 mg twice daily as tolerated[27]. Cardiac monitoring is recommended due to potential QT prolongation[28].
Baclofen and Tizanidine
These GABA-B and alpha-2 adrenergic agonists respectively reduce spasticity[29]. Baclofen dosing starts at 5-10 mg three times daily, titrating to 30-40 mg three times daily[30]. Side effects include sedation, dizziness, and weakness[31]. Tizanidine is an alternative with similar efficacy and side effect profile[32].
Quinine
Historically used for cramps, quinine is no longer recommended due to cardiac toxicity concerns and modest efficacy[33].
Nutritional Intervention
Early nutritional assessment is critical as weight loss and malnutrition are associated with faster disease progression[34]. Percutaneous endoscopic gastrostomy (PEG) tube placement is recommended when weight loss exceeds 10% of body weight or when dysphagia compromises oral intake[35]. Studies show PEG placement is safe in ALS when performed before significant respiratory compromise (FVC < 50%)[36].
Feeding Strategies
Non-Invasive Ventilation (NIV)
NIV improves survival and quality of life in ALS patients with respiratory weakness[38]. Initiation is recommended when symptomatically indicated or when FVC falls below 50% predicted[39]. Bi-level positive airway pressure (BiPAP) is the standard modality, with initial settings of IPAP 12-14 cm H2O and EPAP 4-6 cm H2O[40].
Cough Assist Devices
Mechanical insufflation-exsufflation devices help clear secretions and prevent pulmonary complications[41]. Use is recommended when peak cough flow falls below 270 L/min[42].
Invasive Ventilation
Tracheostomy with long-term mechanical ventilation is an option for patients who desire maximal life extension, though quality of life considerations must be addressed in decision-making[43].
Botulinum Toxin Injections
Botulinum toxin (Botox or Xeomin) injected into salivary glands (parotid and submandibular) effectively reduces drooling[44]. Effects last 3-4 months, with typical dosing of 20-30 units per gland[45].
Anticholinergic Medications
Scopolamine patches, glycopyrrolate, and amitriptyline can reduce saliva production but may cause cognitive side effects in elderly patients[46].
Dextromethorphan/Quinidine (Nuedexta)
This combination is FDA-approved for pseudobulbar affect (PBA) in ALS, significantly reducing episodes of uncontrolled crying or laughing[47]. Dosing is 20/10 mg twice daily[48]. Contraindicated in patients taking MAO inhibitors or with certain cardiac conditions[49].
Multidisciplinary ALS clinics, endorsed by the American Academy of Neurology and European guidelines, improve survival and quality of life compared to standard care[50]. Core team members include:
| Specialty | Role |
|---|---|
| Neurology | Diagnosis, disease-modifying therapy management |
| Pulmonology | Respiratory assessment, NIV initiation |
| Gastroenterology | Nutrition, PEG placement |
| Physical Therapy | Mobility, fall prevention |
| Occupational Therapy | ADL optimization, equipment |
| Speech Therapy | Communication, dysphagia |
| Social Work | Psychosocial support, resources |
| Palliative Care | Symptom management, goals of care |
C9orf72-Targeting Therapies
ASOs and small molecules targeting the C9orf72 hexanucleotide repeat expansion, the most common genetic cause of ALS, are in various trial stages[52]. Waves Therapeutics has an ASO (WTX-114) in Phase I/II for C9orf72-associated ALS[53].
FUS-Targeting Therapies
FUS mutations cause approximately 5% of familial ALS. ASO therapies targeting FUS are in preclinical and early clinical development[54].
Neural Stem Cell Transplantation
Phase I/II trials (NCT01348451, NCT01640067) have evaluated neural stem cell delivery to the spinal cord, showing preliminary safety and potential biological effects[55]. Mesenchymal stem cells with neurotrophic factor secretion are also under investigation[56].
Nuedexta Beyond PBA
Post-hoc analyses suggest potential neuroprotective effects of the dextromethorphan component through sigma-1 receptor agonism[57].
Retigabine
This potassium channel opener was investigated for neuroprotection but the phase II/III SIERRA trial was discontinued due to lack of efficacy[58].
Celecoxib
The COXPEM study is evaluating celecoxib for neuroinflammation modulation in ALS[59].
Ibudilast
This PDE4/MIF inhibitor has completed Phase II trials for ALS (NCT03959592). It reduces neuroinflammation through dual mechanism: PDE4 inhibition increases cAMP to suppress microglial activation, while MIF antagonism blocks a pro-inflammatory cytokine pathway. Clinical trials showed favorable safety with trends toward slower functional decline.
Masitinib
This tyrosine kinase inhibitor targeting mast cells showed promise in a phase III trial, with ongoing regulatory discussions[60].
| Trial | Phase | Intervention | Mechanism | NCT Number |
|---|---|---|---|---|
| TANGELO | III | Ravulizumab | Complement inhibition | NCT04248456 |
| HEALEY | Platform | Multiple | Various | NCT04514367 |
| NOR-ALS | III | Nordimet | Immunomodulation | NCT04655118 |
| RESCUE-ALS | II | CuATSM | Mitochondrial | NCT0408283 |
Common inclusion criteria:
Early integration of palliative care improves quality of life and may extend survival[61]. Referral is recommended:
Pain Management
Dyspnea Management
Psychosocial Support
Key discussions:
| Factor | Impact |
|---|---|
| Age at onset | Older age = worse prognosis |
| Bulbar onset | Shorter survival than limb onset |
| Respiratory onset | Worst prognosis |
| Rapid progression | Shorter survival |
| C9orf72 expansion | Earlier onset, cognitive involvement |
| FVC decline rate | Faster decline = shorter survival |
Chio A, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the literature. Neuroepidemiology. 2013. ↩︎
Renton AE, Chio A, Traynor BJ. State of play in ALS genetics. Nat Rev Neurol. 2014. ↩︎
Hardiman O, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017. ↩︎
Lacomblez L, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996. ↩︎
Bellingham MC. A review of the pharmacological of action of riluzole in treating amyotrophic lateral sclerosis. Am J Alzheimers Dis Other Demen. 2012. ↩︎
Miller RG, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012. ↩︎
Bensimon G, et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994. ↩︎
Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (ALS). J Neurol Sci. 2006. ↩︎
Abe K, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017. ↩︎
Okada M, et al. Long-term safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a post-marketing study. Neurology. 2022. ↩︎
Takahashi F, et al. Edaravone for treatment of amyotrophic lateral sclerosis - focus on its clinical use. J Neurol Sci. 2021. ↩︎
Petrov D, et al. AMX0035: a targeted metabolic therapy for ALS. Nat Rev Neurol. 2017. ↩︎
Paganoni S, et al. Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. N Engl J Med. 2020. ↩︎
Pais P, et al. AMX0035 and Amyotrophic Lateral Sclerosis: An Update on the Development and Clinical Trials. J Clin Med. 2023. ↩︎
Miller T, et al. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020. ↩︎
Valeras MG, et al. Nucleate ASO therapy for SOD1-ALS: a randomized, double-blind, placebo-controlled study. Lancet Neurol. 2023. ↩︎
van den Berg LH, et al. Updated integrated safety analysis of tofersen in patients with SOD1-ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2024. ↩︎
Eisen A, et al. Lamotrigine in ALS: too good to be true? J Neurol Neurosurg Psychiatry. J Neurol Neurosurg Psychiatry. 1999. ↩︎
Pall HS, et al. Lamotrigine (lamictal) in ALS: an open label study. J Neurol. 2003. ↩︎
Gordon PH, et al. Minocycline in ALS: results of an open-label trial. Neurology. 2007. ↩︎
Morrison KE, et al. Phase II trial of lithium in ALS: lack of efficacy in a population-based study. J Neurol Neurosurg Psychiatry. 2013. ↩︎
Oskarsson B, et al. Mexiletine for muscle cramps in ALS: a randomized, double-blind, placebo-controlled trial. Amyotroph Lateral Scler Frontotemporal Degener. 2018. ↩︎
Weiss MD, et al. Mexiletine for the treatment of muscle cramps in ALS: a dose-finding study. Amyotroph Lateral Scler. 2010. ↩︎
Wadman RI, et al. Cardiac safety of mexiletine in ALS: a review of the literature. JNeurol Sci. 2019. ↩︎
Acceptance P. Spasticity and its management in ALS. Eur Med J. 2019. ↩︎
Bhattacharya T, et al. Pharmacological management of spasticity in amyotrophic lateral sclerosis. J Clin Pharm Ther. 2022. ↩︎
Chang E, et al. Spasticity in ALS: treatment strategies. Muscle Nerve. 2018. ↩︎
Nance P, et al. Tizanidine for spasticity in multiple sclerosis and ALS. Neurology. 1999. ↩︎
Elovic EP. Measures of spasticity. Arch Phys Med Rehabil. 2001. ↩︎
Kasarskis EJ, et al. Nutritional status of patients with ALS: a meta-analysis. J Neurol Sci. 1996. ↩︎
Miller RG, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review). Neurology. 2009. ↩︎
Garcia-Zapata MR, et al. Safety of percutaneous endoscopic gastrostomy in ALS patients. Arq Gastroenterol. 2019. ↩︎
Wills AM, et al. Hypercaloric enteral nutrition in amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2014. ↩︎
Bourke SC, et al. Effects of non-invasive ventilation on survival and quality of life in patients with ALS. Lancet. 2006. ↩︎
EFNS Task Force on Management of ALS. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS). Eur J Neurol. 2011. ↩︎
Canty GA, et al. Non-invasive ventilation in ALS: clinical practice update. Chest. 2023. ↩︎
Homnick DN, et al. Mechanical insufflation-exsufflation for airway mucus clearance. Respir Care. 2010. ↩︎
Sancho J, et al. Mechanical insufflation/exsufflation in neuromuscular disease. Arch Bronconeumol. 2010. ↩︎
Cazzolli PA, et al. A retrospective review of long-term invasive ventilation in ALS. Neurology. 2016. ↩︎
Guidubaldi A, et al. Botulinum toxin A versus B in sialorrhea: a comparative study. Parkinsonism Relat Disord. 2011. ↩︎
Chinnapongse R, et al. Injectable botulinum toxin for treatment of sialorrhea in ALS. J Neurol Sci. 2012. ↩︎
Stalker RJ, et al. Anticholinergic therapy for sialorrhea in ALS. J Pain Res. 2018. ↩︎
Pioro EP, et al. Dextromethorphan/quinidine for pseudobulbar affect (PBA): pooled efficacy data. Neurology. 2014. ↩︎
Pattee GL, et al. Safety and efficacy of dextromethorphan/quinidine for pseudobulbar affect in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013. ↩︎
Traynor BJ, et al. Effect of a multidisciplinary ALS clinic on survival. Neurology. 2003. ↩︎
Andersen PM, et al. EFNS guidelines on the clinical management of ALS. Eur J Neurol. 2005. ↩︎
Liu Y, et al. C9orf72-targeted antisense oligonucleotide therapy for ALS. Nat Med. 2024. ↩︎
Scotti MM, et al. Antisense oligonucleotides for targeting FUS in ALS. Mol Ther. 2023. ↩︎
Glass JD, et al. Neural stem cell transplantation in patients with ALS: 24-month follow-up. Neurology. 2022. ↩︎
Oh KW, et al. Phase I trial of mesenchymal stem cells in ALS. Ann Neurol. 2022. ↩︎
Smith R, et al. Neuroprotective effects of dextromethorphan in ALS models. Neurobiol Dis. 2023. ↩︎
ClinicalTrials.gov. COXPEM Study - Celecoxib in ALS. NCT02713984. ↩︎
Mora JS, et al. Masitinib as a treatment for ALS: randomized, double-blind, placebo-controlled trial. Amyotroph Lateral Scler Frontotemporal Degener. 2020. ↩︎
Ng L, et al. Palliative care and ALS: an integrated model of care. Lancet Respir Med. 2023. ↩︎
Brettschneider J, et al. Symptom control in ALS. J Neurol Sci. 2009. ↩︎
Radunovic A, et al. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2017. ↩︎
Oliver DJ, et al. Palliative care in ALS. Handb Clin Neurol. 2013. ↩︎
McCluskey L, et al. ALS and end-of-life care. Neurol Clin. 2020. ↩︎
Chio A, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009. ↩︎